Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients
收藏NIAID Data Ecosystem2026-03-11 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2314944
下载链接
链接失效反馈官方服务：
资源简介：
This is a multicentric single arm, open label trial. In this study patients candidated to a first line of chemotherapy for metastatic colorectal cancer will be treated with 8 cycles of folfoxiri plus bevacizumab plus nivolumab followed by a maintenance with bevacizumab plus nivolumab.
Patients who do not progress during chemotherapy phase will receive bevacizumab plus nivolumab as maintenance therapy.
Patients will be treated until disease progression, unacceptable toxicity or patient/physician decision.
创建时间：
2019-09-15
